knowledge -WSS

knowledge

author：comprehensive 2025-09-30 23:10:57 - browse：6448

Launching your first clinical trial is the type of announcement most biotech executives eagerly anticipate, hoping to celebrate with employees. But for Celsius Therapeutics CEO Tariq Kassum, it’s proving to be more difficult than he anticipated.

That’s because in recent days, Celsius, based in Cambridge, Mass., has been forced to conduct a round of layoffs, sources told STAT. Kassum confirmed around 75% of Celsius’ 40-person team had been laid off, and disclosed that the biotech has also been quietly paring back its pipeline this year. It shut down almost all early-stage research projects, including pausing all of its cancer drug work, in order to conserve enough cash for the Phase 1 trial it announced this week.

“It’s an incredibly bittersweet moment.… The cognitive dissonance there is just really, really hard,” Kassum told STAT. “But I do think that you’re seeing a lot of other companies doing what we are, which is, as painful as it is, to focus on the nearest term value drivers, the things that can get to patients the quickest, and make the painful decisions that allow you to live to fight another day.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Mass General, Mayo Clinic look to monetize custom

hotspot

knowledge

WSS

The inclusion problem at the heart of rehabilitation research

High breast density mammograms need follow

Senator probes 340B programs at Cleveland Clinic, Bon Secours

Paxlovid should be available without a positive Covid test

CVS is on a mission to consolidate health care. Will it work?

Maisha Meds is a PBM, but don't call it that

explore

knowledge

leisure time

At least 13 dead in Texas as scorching temps continue

Listen: Who gets the credit for GLP

23andMe had bad news about my health. I wish a person had delivered it

Intercept Pharmaceuticals sells itself for less than $1 billion

Medical leaders decry Supreme Court decision on affirmative action

What causes osteoarthritis? Researchers study link to brain protein

Moonlake's readout produced a cash windfall. Risks remain

Printout prescription drug information shouldn’t go digital

Walensky prepares to leave CDC — and Congress — behind

How the Dana

Wikipedia

Prior authorization reform is both possible and imperative

Ionis has late

Mindstrong's demise and the future of mental health care

Health tech startups drop sharply from 2021 highs

High breast density mammograms need follow

TikTok, Instagram influencers need more rules for drug ads

hotspot

hotspot

knowledge

focus